Synairgen is confident to get a positive outcome in Part 2 study of Phase 2 trial of its antiviral therapy for Chronic Obstructive Pulmonary Disorder (COPD) patients, in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection, after the first part showed positive results.
Synairgen said in the press release that the data from the first part of its ongoing Phase II trial of its wholly-owned antiviral therapy inhaled interferon beta (IFN-beta) in COPD patients, shows that treatment with IFN-beta boosted the lungs’ antiviral defences, increasing Synairgen’s confidence in the likelihood of a positive outcome in Part 2 of the study in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection.
Professor Tom Wilkinson, who lead the SG015 study, said: “Respiratory virus infections, such as the common cold and flu, are a major cause of exacerbations of COPD, which are the second most common cause of unplanned hospital admission in England, so there is a real need for a treatment that helps patients when they have a cold or flu infection. The biomarker data from Part 1 indicate that we are ‘switching on’ antiviral defences in the lungs which we hope will translate into a clinical benefit in Part 2 of the study, when patients take either placebo or inhaled IFN-beta for 14 days when they have a confirmed respiratory viral infection. The trial is progressing well, and we are on track to complete the study during this coming winter virus season.”